La cadena de opciones muestra datos clave de las opciones de acciones de BriaCell Therapeutics a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para BriaCell Therapeutics..

BriaCell Therapeutics (NASDAQ:BCTX) Bolsa, Cadena de Opciones

BriaCell Therapeutics

BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.

Pre-Market Outlook

Markets

Movers

ACON

AEON

BCTX

CPHC

EKSO

Sunrise New Energy Co., Ltd - Ordinary Shares

EPOW

KITT

LDTC

MBOT

MEGL

MNSO

NSTS

SPPL

WFCF

Explora los mayores movimientos en el premercado con ganancias superiores al 100% y pérdidas significativas antes de la apertura.

Acciones de Smart Share Global se disparan un 44%; 20 acciones que se mueven en el premercado

BriaCell Therapeutics Corp. - Common Shares

BriaCell Therapeutics Corp

INmune Bio Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INMB#NASDAQ">INMB</a>) stock is trading higher on Friday, with a session volume of 10.26 million compared to the average volume of 519.5K, <a href="https://www.benzinga.com/pro/feature/newsfeed" target="_blank" rel="noreferrer noopener">per data from Benzinga Pro</a>.
On Thursday,  INmune Bio said it will host a conference call on Monday, June 30, to present topline data from the Phase 2 MINDFuL trial in early <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">Alzheimer&#8217;s disease</a>.
The MINDFuL study investigates XPro in patients with mild cognitive impairment or Alzheimer's disease with brain inflammation.
The MINDFuL study <a href="https://inmunebio.com/index.php/clinical-trials/mindful-section" target="_blank" rel="noreferrer noopener">will</a> compare XPro to placebo (an injection that looks like the investigational drug but does not contain active medicine) to determine whether XPro affects memory, functioning and behavior, and whether it is safe and tolerable.
In November 2024, INmune Bio completed randomization of patients for <a href="https://www.benzinga.com/pressreleases/24/11/g41939489/inmune-bio-inc-announces-final-enrollment-of-208-patients-in-phase-2-trial-in-early-alzheimers-dis" target="_blank" rel="noreferrer noopener">its Phase 2 trial</a>. &#8220;The trial ended up overenrolled with a total of 208 patients, 56% of whom were categorized as mild AD and 44% as MCI,&#8221; said RJ Tesi, CEO of INmune Bio
In September 2024, the company announced that the results of an additional analysis of blinded data from its AD02 Phase II Alzheimer&#8217;s Disease trial demonstrated&nbsp;exceptional performance of the novel cognitive measure EMACC and a highly significant correlation between EMACC and the Clinical Dementia Rating-Sum of Boxes (CDR-SB), the <a target="_blank" href="https://www.benzinga.com/pressreleases/24/09/g40897550/inmune-bio-announces-results-of-additional-blinded-interim-analysis-of-phase-2-alzheimers-disease-" rel="noreferrer noopener">accepted endpoint for AD trials.</a>
Key Findings: An independent review confirmed a highly significant correlation (p&lt;0.001) between baseline scores on EMACC and CDR-SB, the secondary endpoint in the AD02 trial.
The correlation of EMACC, when measured during the screening process and again at the first study visit before treatment, was found to be 0.93.
The difference in EMACC performance between patients with CDR global ratings of 0.5 (prodromal AD) and those rated 1.0 (mild dementia) was very large, with an effect size (Cohen&#8217;s d) of 0.87 (p&lt;.0001)
XPro is a next-generation inhibitor of tumor necrosis factor (TNF) that is currently in clinical trial and acts differently than currently available TNF inhibitors in that it neutralizes soluble TNF (sTNF), without affecting trans-membrane TNF (tmTNF) or TNF receptors.
XPro could have potential substantial beneficial effects in patients with neurologic disease by <a href="https://www.benzinga.com/pressreleases/25/06/g46127038/inmune-bio-inc-to-announce-top-line-results-from-mindful-phase-2-trial-in-early-alzheimers-on-mond" target="_blank" rel="noreferrer noopener">decreasing neuroinflammation</a>.
INMB Price Action: INMB stock is up 74.68% at $10.97 at publication on Friday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/m-a/25/06/46138385/deal-dispatch-darden-bahama-breeze-nba-ma-heats-up" target="_blank" rel="noreferrer noopener">Deal Dispatch: Darden Cools On Bahama Breeze, NBA M&amp;A Heats Up</a></li>
</ul>
Photo: khunkornStudio via Shutterstock

Biotech

News

Health Care

Trading Ideas

General

INMB

INmune Bio Stock Soars Friday On Alzheimer's Treatment Hopes

<a href="https://www.reuters.com/legal/litigation/us-supreme-court-expected-rule-obamacare-preventive-care-task-force-2025-06-27/">https://www.reuters.com/legal/litigation/us-supreme-court-expected-rule-obamacare-preventive-care-task-force-2025-06-27/</a>

'US Supreme Court preserves key element of Obamacare preventive care'- Reuters

Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) is exploring the acquisition of voice-cloning <a href="https://www.benzinga.com/topic/artificial-intelligence" target="_blank" rel="noreferrer noopener">artificial intelligence startup</a> PlayAI and some of its employees.
Financial terms of the transaction remain undisclosed, Bloomberg <a target="_blank" href="https://www.bloomberg.com/news/articles/2025-06-26/meta-in-talks-to-buy-ai-voice-startup-playai-in-push-for-talent?srnd=phx-technology&amp;sref=TBDibEcD" rel="noreferrer noopener">reported</a> on Thursday, citing unnamed sources familiar with the matter.
The move marks Meta&#8217;s plan to build a &#8220;superintelligence&#8221; lab to unlock value. The update coincided with growing competition in the AI voice assistant space. 
In March, OpenAI&nbsp;updated its&nbsp;ChatGPT&nbsp;voice assistant to make it more <a target="_blank" href="https://www.benzinga.com/tech/25/03/44468019/openai-says-its-making-chatgpt-voice-assistant-sound-more-like-a-human-and-it-wont-interrupt-as-much" rel="noreferrer noopener">personable and responsive</a>.
Also Read: <a href="https://www.benzinga.com/markets/tech/25/06/46117348/meta-secures-more-clean-energy-for-power-hungry-ai-and-data-center-growth" target="_blank" rel="noreferrer noopener">Meta Secures More Clean Energy For Power Hungry AI And Data Center Growth</a>
Also in March, <a target="_blank" href="https://www.benzinga.com/markets/equities/25/03/44401097/soundhound-ai-integrates-nvidias-software-to-accelerate-voice-ai-technologies" rel="noreferrer noopener">conversational AI solutions</a> provider&nbsp;SoundHound AI&nbsp;expanded its partnership&nbsp;with&nbsp;Nvidia Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) to enhance the speed and efficiency of its AI-driven solutions.
In June, the parent company of Facebook and Instagram invested $14.3 billion in <a href="https://www.benzinga.com/markets/tech/25/06/45880561/meta-on-the-verge-of-a-15-billion-deal-with-scale-ai-report" target="_blank" rel="noopener">data-labeling startup</a> Scale AI and tapped its CEO to lead its AI team.
Meta CEO Mark Zuckerberg had tapped AI researchers from Google, Sesame AI, and OpenAI for its AI team. Meta reportedly discussed acquiring <a href="https://www.benzinga.com/markets/equities/25/06/46070157/meta-reportedly-tried-to-buy-ai-video-startup-runway-before-14-billion-scale-ai-bet-report" target="_blank" rel="noreferrer noopener">AI video startup</a> Runway before completing its Scale AI investment.
Meta&#8217;s other AI acquisition pursuits in 2025 included Safe Superintelligence and Perplexity AI.
Meta held $70.23 billion in <a target="_blank" href="https://www.benzinga.com/news/earnings/25/04/45117948/meta-q1-earnings-eps-beat-revenue-up-16-ai-approaches-1-billion-monthly-actives-capital-expenditures-forecast-raised" rel="noreferrer noopener">cash and equivalents</a> as of March 31, 2025.
<a target="_blank" href="https://www.benzinga.com/25/05/45144725/meta-analysts-highlight" rel="noreferrer noopener">Wall Street firms</a>, including JPMorgan, Goldman Sachs, and KeyBanc, noted Meta as a leader in the digital ad space backed by strong platform demand, continued momentum in the ad business, and capex investments.
Price Action: META stock was trading higher by 0.75% to $731.52 at last check Friday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/06/46134725/google-cloud-hires-former-oracle-cfo-as-ai-race-heats-up" target="_blank" rel="noreferrer noopener">Google Cloud Hires Former Oracle CFO As AI Race Heats Up</a></li>
</ul>
Photo: Skorzewiak/Shutterstock

Tech

Media

AAPL

GOOGL

MSFT

NVDA

Meta's Play For Voice AI Could Shake Up The Competition

Compass Point analyst Ed Engel maintains Robinhood Markets (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) with a Buy and raises the price target from $64 to $96.

Price Target

Analyst Ratings

HOOD

Compass Point Maintains Buy on Robinhood Markets, Raises Price Target to $96

<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4458101-1&amp;h=1504814313&amp;u=https%3A%2F%2Fwww.simon.com%2F&amp;a=Simon">Simon</a>&#xAE;, a real estate investment trust engaged in the ownership of premier shopping, dining, entertainment and mixed-use destinations, and Swire Properties, Inc., a leading developer of mixed-use, commercial, and residential properties in Miami, today announced that Simon has acquired Swire Properties' interest in the retail and parking at Brickell City Centre.
Prior to the acquisition, Simon owned a 25%, non-managing interest in the retail at Brickell City Centre, and, following this transaction, will wholly own and manage the asset.

Simon Acquires Swire Properties' Interest In Retail And Parking At Brickell City Centre; Terms Undisclosed

Reuters Cites Tass Saying Putin Says Russia Is Ready For New Round Of Talks In Istanbul

Good Morning Traders! In today&#8217;s Market Clubhouse Morning Memo, we will discuss SPY, QQQ, AAPL, MSFT, NVDA, GOOGL, META, and TSLA.
Our proprietary formula, exclusive to Market Clubhouse, dictates these price levels. This dynamic equation takes into account price, volume, and options flow. These levels are updated every day and shared with all Clubhouse Members, prior to the opening of the market.
We recommend closely monitoring these stocks, and be prepared to leverage potential breakouts or reversals. As always, stay alert and ready to adjust your tactics based on the market&#8217;s pulse to optimize your trading gains. Now, let&#8217;s dive into the stock analysis:
SPDR S&amp;P 500 ETF Trust (SPY)
SPY is currently trading around our critical area of 613.46. For bullish continuation, we&#8217;d like to see buyers swiftly take the auction upwards toward 614.75. If momentum sustains above this level, watch for price stability at our key area of 615.74. Holding firm at this zone during normal market conditions could propel SPY upward, targeting 616.31 next. Our upper bullish target for today&#8217;s session stands confidently at 617.21.&nbsp;
On the flip side, should 613.46 break down under selling pressure, bears are likely to press lower, initially challenging 612.68. Further bearish activity could send price down to test the robustness of 611.39. Continued heavy selling will expose 610.63, a significant defensive point. If the market turns notably bearish today, we anticipate an extended downward move toward our lower bear objective at 609.33.
Invesco QQQ Trust Series 1 (QQQ)
QQQ is presently trading close to our pivotal mark of 547.65. Bulls need to firmly secure this level and establish buying interest to advance toward 549.59. Confirmation of strength here could propel the auction higher, testing 550.60. A robust bullish scenario could open the gates to further upside, bringing 553.46 into focus. Our primary bullish objective for QQQ today is at 555.21.&nbsp;
Conversely, if buying stalls around 547.65, bearish momentum may swiftly return, targeting an aggressive push down to 545.14. A continued sell-off could force prices further down to assess strength at 543.22. Persistent bearishness would likely bring about a decisive test of 542.31. Losing this crucial level decisively would see QQQ vulnerable toward our lower bear target at 540.60.
Apple Inc. (AAPL)
Apple shares are currently positioned near our central point of 202.29. Bulls must maintain strong support at this level, looking for momentum to lift prices toward 203.48 initially. Persistent bullishness would likely extend gains to 204.33. A decisive upward thrust could propel Apple towards today&#8217;s bullish ambition at 205.54.&nbsp;
Should selling pressure intensify and Apple fail to defend 202.29 during active trading, bears could target a downward test at 201.29. A sustained bearish auction may see sellers pushing prices down further to 200.53. Continuation of the negative sentiment could expose 199.51. If bearish momentum escalates, Apple&#8217;s price could ultimately move toward our lower bearish objective at 198.79.
Microsoft Corp. (MSFT)
Microsoft is presently auctioning around our critical pivot of 496.90. Bulls will need to hold strong above 498.27 to confidently lift the market toward a pivotal test of 499.79. Solidifying support at this key level during regular market hours could ignite an upward momentum toward 501.34. Sustained bullish activity may carry price action to our high bullish destination at 504.11 today.&nbsp;
If Microsoft loses strength and falls below 496.90, bears are anticipated to push prices lower towards an initial support test at 495.11. Should bearish momentum intensify, the market might test lower ground at 493.62. Persistent selling could send prices down to 491.33, and continued downward force could ultimately lead Microsoft towards our lowest bearish target at 489.88.
NVIDIA Corporation (NVDA)
NVIDIA is currently auctioning near our essential zone of 156.49. For bullish continuation, bulls need to decisively take the auction upward to test and establish support at 158.34. Positive momentum could further propel the price action toward 160.64. If buying strength persists throughout today&#8217;s session, expect a potential move upward toward 162.15. Our ambitious bullish target for NVIDIA today is 164.35.&nbsp;
On the downside, if NVIDIA struggles to hold the support at 156.49, bears are likely to aggressively probe lower levels at 154.64. Persistent bearish strength could lead sellers to push prices even lower towards 153.23. Further weakening would prompt a test of 151.99. Continued bearish pressure may ultimately see NVIDIA reaching down to our lower bear target at 150.32.
Alphabet Inc Class A (GOOGL)
Alphabet shares are currently trading around our critical price level of 174.01. Bulls need to maintain this price as firm support, setting the stage for a push higher toward 175.12. If bullish energy is sustained, Alphabet could continue rallying to our primary upside target at 176.23 today.&nbsp;
If buyers falter and 174.01 fails as support during today&#8217;s trading session, bears will likely step in decisively to probe downward at 172.28. Further bearish momentum may bring the price action to test the critical support at 171.14. An intensified sell-off scenario could drive Alphabet lower toward today&#8217;s bear target at 169.34.
Meta Platforms Inc (META)
Meta is currently auctioning around our pivotal level at 729.50. Bulls should secure strong support here to lift the price action confidently towards the immediate upside target at 733.41. Sustained bullish momentum could then carry the auction higher, bringing 736.12 into play. Extended bullish buying today might push Meta toward our ambitious bullish target at 738.07.&nbsp;
Should Meta fail to maintain the 729.50 support during regular market hours, bears could aggressively target downside pressure initially at 727.04. Continued selling activity may lead to a deeper retracement toward 725.04. A decisive breakdown at this level could set the stage for an intensified bear move towards our lower bear target today at 722.94.
Tesla Inc. (TSLA)
Tesla shares are currently trading around our crucial price point of 327.59. Bullish traders need to push the auction firmly higher toward 333.93 initially. Strong buying activity could propel price significantly upward toward the critical price level of 340.97. Continued bullish activity today might result in testing even higher at 346.64. Strong positive momentum would see Tesla reach towards our ultimate bullish objective today at 350.87.&nbsp;
On the downside, failure to maintain the critical support of 327.59 could trigger bearish action, sending prices swiftly lower to initially test 322.52. Persistent selling pressure would further challenge lower at 315.93. A clear breach of this crucial support could bring about a bearish scenario targeting today&#8217;s low bear level at 312.42.
Final Word: Today&#8217;s session opens with key economic data, including the release of May&#8217;s PCE Price Index, alongside Personal Income and Spending figures, all scheduled at 8:30 AM ET. Concurrently, Canada&#8217;s April GDP data will also be released, providing additional macroeconomic insight. At 10:00 AM ET, traders will receive the Final University of Michigan Sentiment figures for June, along with critical updates to the 1 Year and the 5-10 Year Inflation Outlook. At 11:00 AM ET, attention will shift to the Kansas City Fed Services Activity report, potentially influencing sector-specific sentiment.&nbsp;
Additionally, market participants should closely monitor scheduled remarks from Federal Reserve officials Hammack and Cook at 9:15 AM ET, as their commentary could inject volatility into trading, especially given recent market strength at record-high price levels. Expect an active trading environment, maintain risk management practices, and prioritize capital preservation heading into the weekend. Good luck and trade safely!
For a limited time during our special promotion, you can join RIPS and get a full access pass to Market Clubhouse for 7 full days for just $7. Check it out at <a href="https://marketclubhouse.club/7Days/" title="https://marketclubhouse.club/7Days/">https://marketclubhouse.club/7Days/</a> where you can trade live with him and tap into his wealth of knowledge and experience. You can also catch Rips on his live day trading streams every Monday-Friday at 8 am EST on the Market Clubhouse YouTube channel: <a href="https://www.youtube.com/@MarketClubhouse" title="https://www.youtube.com/@MarketClubhouse">https://www.youtube.com/@MarketClubhouse</a>.

Equities

Broad U.S. Equity ETFs

Technicals

Opinion

Signals

How To Trade SPY, Top Tech Stocks As Core Inflation Edges Up Above Expectations

Reuters Cites Ifax Saying Putin Says Time And Venue Of Third Round Of Talks With Ukraine Still To Be Agreed

YORKU

Trading Halt: Halt status updated at 10:35:00 AM ET: Quotation Resumption: IPO Security - Released for Quotation

Redburn Atlantic analyst Olivier Brochet upgrades Boeing (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) from Neutral to Buy and raises the price target from $180 to $275.

Upgrades

Redburn Atlantic Upgrades Boeing to Buy, Raises Price Target to $275

IES Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IESC#NASDAQ">IESC</a>) has outperformed the market over the past 5 years by 50.64% on an annualized basis producing an average annual return of 65.46%. Currently, IES Hldgs has a market capitalization of $5.76 billion. 
Buying $100 In IESC: If an investor had bought $100 of IESC stock 5 years ago, it would be worth $1,254.59 today based on a price of $290.01 for IESC at the time of writing.
<h3>IES Hldgs's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751034631_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

IESC

If You Invested $100 In This Stock 5 Years Ago, You Would Have This Much Today

B of A Securities analyst Ruplu Bhattacharya maintains Concentrix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNXC#NASDAQ">CNXC</a>) with a Neutral and lowers the price target from $65 to $61.

CNXC

B of A Securities Maintains Neutral on Concentrix, Lowers Price Target to $61

WIIM

CNXC stock has given up its prior loss. Concentrix shares were trading lower after the company reported a Q2 adjusted EPS miss and narrowed its FY25 adjusted EPS guidance.

<a href="https://www.bloomberg.com/news/articles/2025-06-27/alibaba-unveils-latest-ai-service-for-images-in-push-for-users">https://www.bloomberg.com/news/articles/2025-06-27/alibaba-unveils-latest-ai-service-for-images-in-push-for-users</a>

BABA

'Alibaba Unveils Latest AI Service for Images in Push for Users'- Bloomberg

B of A Securities analyst Lorraine Hutchinson maintains ODDITY Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ODD#NASDAQ">ODD</a>) with a Buy and raises the price target from $68 to $80.

B of A Securities Maintains Buy on ODDITY Tech, Raises Price Target to $80

Locafy Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCFY#NASDAQ">LCFY</a>) shares are skyrocketing Friday morning after the company announced a strategic partnership with a leading U.S. online reputation management platform.
What To Know: Locafy says the <a href="https://www.benzinga.com/pressreleases/25/06/g46136767/locafy-partners-with-leading-u-s-reputation-platform-plans-to-scale-deployment-of-ai-ready-search-">collaboration</a> will syndicate business listings for the partner&#8217;s clients, including real estate and mortgage professionals, across a wide range of digital directories, search engines and voice assistants.
This agreement provides Locafy with what the company says will be a significant foothold in the U.S. market and sets the stage for broader adoption of its new AI-powered search and engagement tools. 
Locafy will create &#8220;AI Search Ready&#8221; landing pages for clients, designed to be primary sources for major AI platforms like ChatGPT, Gemini and Perplexity.
&#8220;We&#8217;ve created the ultimate location-based digital marketing solution,&#8221; said Locafy CEO Gavin Burnett. He highlighted that the company&#8217;s technology not only syndicates listings but also boosts local search rankings for valuable keywords.
Price Action: According to data from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, LCFY shares are trading higher by 225% to $8.30 Friday morning. The stock has a 52-week high of $12.22 and a 52-week low of $2.28.
Read Also: <a href="https://www.benzinga.com/pressreleases/25/06/g46136767/locafy-partners-with-leading-u-s-reputation-platform-plans-to-scale-deployment-of-ai-ready-search-">Locafy Partners with Leading U.S. Reputation Platform &#8211; Plans to Scale Deployment of &#8220;AI-Ready&#8221; Search Solutions</a>
<h2 class="wp-block-heading">How To Buy LCFY Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Locafy&#8217;s case, it is in the Information Technology sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
Image: Shutterstock

LCFY

Locafy (LCFY) Stock Is Up Over 200% Today: What's Going On?

Nuburu Inc. (NYSEAMERICAN: BURU) announced Friday that it is making <a href="https://www.benzinga.com/pressreleases/25/06/b46137628/nuburu-advances-defense-tech-transformation-with-strategic-acquisitions-and-50m-military-deploymen" target="_blank" rel="noreferrer noopener">steady progress</a> in its strategic pivot toward defense and security technologies, which is highlighted by its planned acquisition of Italy-based Tekne SpA. The stock rallied following the announcement.
The deal, currently under review through Italy&#8217;s Golden Power process, is progressing as expected, with indications pointing to a favorable outcome.
Executive Chairman Alessandro Zamboni called Tekne&#8217;s &#8220;Tactical Bubble&#8221; a critical component in Italy&#8217;s military modernization. 
Also Read: <a href="https://www.benzinga.com/analyst-stock-ratings/price-target/25/06/45909938/optics-rebound-in-sight-j-p-morgan-boost-targets-on-coherent-lumentum-amid-tec" target="_blank" rel="noreferrer noopener">Optics Rebound In Sight: J.P. Morgan Boost Targets On Coherent, Lumentum Amid Tech Shift Easing</a>
The real-time battlefield system enhances communication, decision-making, and situational awareness across deployed units. It features integrated defenses against threats such as drones and electromagnetic interference.
Valued at over €50 million euros (approximately $58.5 million), Tekne&#8217;s ongoing contract with the Italian Ministry of Defense includes full deployment of the Tactical Bubble platform, which was recently showcased in large-scale exercises &#8220;Stella Alpina&#8221; and &#8220;Scudo 25.&#8221;
Alongside the Tekne deal, Nuburu is also advancing the acquisition of a SaaS startup designed to bolster cyber and operational resilience in sensitive infrastructure. Both transactions remain subject to regulatory and shareholder approval, with due diligence and audits underway.
Zamboni said the progress validates Nuburu&#8217;s strategy to diversify beyond laser tech and into high-growth verticals like defense-tech and homeland security. The company is also investing in emerging technologies, including Agentic AI while exploring fintech integration through its partnership with Supply@ME Capital Plc.
Related ETFs: SPDR S&amp;P Aerospace &amp; Defense ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XAR#NYSE">XAR</a>), iShares U.S. Aerospace &amp; Defense ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ITA#BATS">ITA</a>).
Price Action: BURU shares are trading higher by 16.29% at $0.40 on Friday&#8217;s last check.
Read Next:
<a href="https://www.benzinga.com/news/politics/25/06/46111425/natos-new-5-target-for-defense-a-win-for-trump-carney-turns-to-critical-minerals" target="_blank" rel="noreferrer noopener">NATO&#8217;s New 5% Target For Defense A Win for Trump; Carney Turns To Critical Minerals</a>
Image by DC Studio via Shutterstock

BURU

iShares Dow Jones US Aerospace & Defense Index Fund

Why Is Nuburu Stock Soaring On Friday?

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Citigroup analyst George Gianarikas downgraded the rating for Lyft, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYFT#NASDAQ">LYFT</a>) from Buy to Hold and lowered the price target from $22 to $14. Lyft shares closed at $15.85 on Thursday. <a href="https://www.benzinga.com/quote/AFRM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Canaccord Genuity analyst George Gianarikas downgraded Uber Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>) from Buy to Hold and cut the price target from $90 to $84. Uber shares closed at $93.12 on Thursday. <a href="https://www.benzinga.com/quote/AFRM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Stephens &amp; Co. analyst Trey Grooms downgraded GMS Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMS#NYSE">GMS</a>) from Overweight to Equal-Weight and maintained the price target of $95. GMS shares closed at $98.54 on Thursday. <a href="https://www.benzinga.com/quote/AFRM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Baird analyst David George downgraded Bank of America Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>) from Outperform to Neutral and maintained the price target of $52. Bank of America shares closed at $47.46 on Thursday. <a href="https://www.benzinga.com/quote/AFRM/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying UBER stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/UBER/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="552" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/27101911/image-426-1024x552.png" alt="" class="wp-image-965002" style="width:612px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/27101911/image-426-1024x552.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/27101911/image-426-300x162.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/27101911/image-426-768x414.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/27101911/image-426.png 1153w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/46115042/top-2-tech-and-telecom-stocks-you-may-want-to-dump-in-june">Top 2 Tech And Telecom Stocks You May Want To Dump In June</a> </li>
</ul>
Photo via Shutterstock

Downgrades

LYFT

UBER

This Uber Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Friday

Bone Biologics Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBLG#NASDAQ">BBLG</a>) stock is trading higher on Friday, with a session volume of 17.22 million compared to the average volume of 38.795K <a target="_blank" href="https://www.benzinga.com/pro/feature/newsfeed" rel="noreferrer noopener">as per data from Benzinga Pro</a>.
The company filed a patent application with the U.S. Patent and Trademark Office (USPTO) for its <a href="https://www.benzinga.com/pressreleases/25/06/b46135732/bone-biologics-files-patent-application-for-bone-regeneration-technology" target="_blank" rel="noreferrer noopener">preclinical NELL-1 protein</a>.
Bone Biologics is focusing development efforts for its bone graft substitute product on bone regeneration in spinal fusion procedures. It additionally has rights to trauma and osteoporosis applications.
The patent application is directed to compositions of rhNELL-1 polypeptide and uses thereof for treating bone conditions.
&#8220;This patent application marks a major milestone in our mission to bring effective treatments to spine fusion patients,&#8221; said Jeffrey Frelick, CEO of Bone Biologics.
If approved, the patent application will strengthen Bone Biologics&#8217; intellectual property portfolio and support the company&#8217;s strategic plan to advance the clinical development program.
Additionally, on Friday, Bone Biologics priced its public offering of 1.25 million shares, Series D warrants to purchase up to 1.25 million shares of common stock, and Series E short-term warrants to purchase up to 1.25 million at $4 per share and accompanying warrants.
The Series D and Series E warrants will have an exercise price of $4 per share.
Total gross proceeds are expected to be $5.0 million. If fully exercised on a cash basis, the warrants could generate $10 million in additional gross proceeds to the company.
The company plans to use the proceeds to fund clinical trials, maintain and extend its patent portfolio and for working capital and other general <a href="https://www.benzinga.com/pressreleases/25/06/b46138329/bone-biologics-announces-pricing-of-5-0-million-public-offering" target="_blank" rel="noreferrer noopener">corporate purposes.</a>
On Thursday, Bone Biologics said it regained compliance with the minimum bid price requirement <a href="https://www.benzinga.com/pressreleases/25/06/b46127829/bone-biologics-regains-compliance-with-nasdaq-continued-listing-requirements" target="_blank" rel="noreferrer noopener">under the Nasdaq Listing</a>.
Earlier this month, Bone Biologics announced a reverse stock split of its shares of common stock <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/b45811307/bone-biologics-announces-1-for-6-reverse-stock-split" rel="noreferrer noopener">at a ratio of 1-for-6</a>.
BBLG Price Action: Bone Biologics stock is up 20.31% at $5.01 at publication on Friday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/06/46137965/crwv-corz-potential-deal-could-unlock-2-8-billion-hidden-value-for-bitcoin-miner-says-morgan-stanley" target="_blank" rel="noreferrer noopener">CRWV–CORZ Potential Deal Could Unlock $2.8 Billion Hidden Value For Bitcoin Miner, Says Morgan Stanley</a></li>
</ul>
Photo: Shutterstock

Financing

Offerings

BBLG

Why Is Bone Biologics Stock Surging On Friday?

B of A Securities analyst Bryan Spillane downgrades Molson Coors Beverage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAP#NYSE">TAP</a>) from Buy to Neutral and lowers the price target from $65 to $50.

Comments

BriaCell Therapeutics

BriaCell Therapeutics (BCTX) Opciones

Loading...

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL